Javier Ramos Paradas

Mr. Javier Ramos Paradas

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2016 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
EBElena de Blas
Elena de Blas
MEMaría Cristina Estañ
María Cristina Estañ
MFMaría del Carmen Gómez de Frutos
María del Carmen Gómez de Frutos
JPJavier Ramos Paradas
Javier Ramos Paradas
MBMaria Del Carmen Boyano-Adánez
Maria Del Carmen Boyano-Adánez
PAPatricio Aller
Patricio Aller
The glycolysis inhibitor 2-deoxy-d-glucose (2-DG) is a safe, potentially useful anti-tumour drug, but its efficacy is normally low when used alone. Recent studies indicated that 2-DG stimulates the PI3K/Akt and MEK/ERK defensive pathways, which limits the apoptotic efficacy in tumour cell lines. We hypothesized that co-treatment with selected polyphenols could improve 2-DG-provoked apoptosis by preventing defensive kinase activation. Cell proliferation was measured by cell counting or the MTT assay. Cell cycle, apoptosis and necrosis were determined by propidium iodide staining and/or annexin V labeling followed by flow cytometry. Mitochondria pore transition and depolarization were determined by calcein-ATM or rhodamine 123 labeling followed flow cytometry. Intracellular reactive oxygen species and GSH were determined by dichlorodihydrofluorescein diacetate or monochlorobimane labeling followed by flow cytometry or fluorimetry. Expression and phosphorylation of protein kinases were analyzed by the Western blot. (i) 2-DG-provoked apoptosis was greatly potentiated by co-treatment with the sub-lethal concentrations of the flavonoid quercetin in human HL60 acute myeloblastic leukemia cells. Allowing for quantitative differences, apoptosis potentiation was also obtained using NB4 promyelocytic and THP-1 promonocytic cells, using curcumin or genistein instead of quercetin, and using lonidamine instead of 2-DG, but not when 2-DG was substituted by incubation in glucose-free medium. (ii) Quercetin and 2-DG rapidly elicited the opening of mitochondria pore transition, which preceded the trigger of apoptosis. (iii) Treatments did not affect GSH levels, and caused disparate effects on reactive oxygen species generation, which did not match the changes in lethality. (iv) 2-DG and lonidamine stimulated defensive Akt and ERK phosphorylation/activation, while glucose starvation was ineffective. Polyphenols prevented the stimulation of Akt phosphorylation, and in some cases also ERK phosphorylation. In addition, quercetin and 2-DG stimulated GSK-3α,β phosphorylation/inactivation, although with different isoform specificity. The use of pharmacologic inhibitors confirmed the importance of these kinase modifications for apoptosis. The present in vitro observations suggest that co-treatment with low concentrations of selected polyphenols might represent a manner of improving the poor anti-tumour efficacy of some glycolytic inhibitors, and that apoptosis potentiation may be at least in part explained by the regulation of defensive protein kinase activities.

Verified
Journal Article
Open access
PDF file
JPJavier Ramos Paradas
Javier Ramos Paradas
DGDavid Gómez-Sánchez
David Gómez-Sánchez
ARAranzazu Rosado
Aranzazu Rosado
AUAlvaro Conrado Ucero
Alvaro Conrado Ucero
IFIrene Ferrer
Irene Ferrer
LPLuis Paz-Ares
Luis Paz-Ares
Lung cancer is the leading cause of cancer mortality worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent histology. While immunotherapy with checkpoint inhibitors has shown outstanding results in NSCLC, the precise identification of responders remains a major challenge. Most studies attempting to overcome this handicap have focused on adenocarcinomas or squamous cell carcinomas. Among NSCLC subtypes, the molecular and immune characteristics of lung large cell carcinoma (LCC), which represents 10% of NSCLC cases, are not well defined. We hypothesized that specific molecular aberrations may impact the immune microenvironment in LCC and, consequently, the response to immunotherapy. To that end, it is particularly relevant to thoroughly describe the molecular genotype–immunophenotype association in LCC–to identify robust predictive biomarkers and improve potential benefits from immunotherapy. We established a cohort of 18 early-stage, clinically annotated, LCC cases. Their molecular and immune features were comprehensively characterized by genomic and immune-targeted sequencing panels along with immunohistochemistry of immune cell populations. Unbiased clustering defined two novel subgroups of LCC. Pro-immunogenic tumors accumulated certain molecular alterations, showed higher immune infiltration and upregulated genes involved in potentiating immune responses when compared to pro-tumorigenic samples, which favored tumoral progression. This classification identified a set of biomarkers that could potentially predict response to immunotherapy. These results could improve patient selection and expand potential benefits from immunotherapy.

1 October 2019 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
EGEva Maria Garrido-Martin
Eva Maria Garrido-Martin
JPJavier Ramos Paradas
Javier Ramos Paradas
SPS. Hernandez Prieto
S. Hernandez Prieto
ESE. Sanchez
E. Sanchez
ARA. Rosado
A. Rosado
LPL. Paz-Ares
L. Paz-Ares
Tumour mutational burden (TMB) is an emerging predictive biomarker for patients with NSCLC treated with checkpoint inhibitors. A number of gene panels are available for TMB calculation, each with different characteristics, including the number of genes and the selected individual genes, and distinct informatics algorithms that may lead to different results. We have performed a correlation study of 3 panels in a large cohort of clinically annotated NSCLC patients. We have blindly evaluated the concordance of tissue TMB assessments of two different commercially available panels: TSO500 (performed at HU 12 de Octubre) and Oncomine TML (performed at CIOCC), with Foundation One® CDx (F1CDx-Penzberg, Germany). A cohort of 100 early stage NSCLC tumour samples is being utilized. PD-L1 expression was analyzed in all samples with 22C3 PharmDX. The determination of TMB for all panels was calculated as total number of mutations (synonym plus non-synonym) per megabase of exonic DNA. Four samples did not have enough sequencing depth for TML panel (n = 96 was used for all correlations). TMB values correlated with F1CDx with a R2 =0.8775 for TSO500; and with a R2 = 0.8119 for TML. The correlation between TSO500 and TML was R2 = 0.8545. Results obtained for each panel are indicated in the table below. Additionally, TMB values were evaluated in the samples grouped by < 1%, >1% and >50% of PD-L1 expression. In tumours PD-L11% (n = 41), TMB values correlated with F1CDx with a R2 = 0.7466 (TSO500) and a R2 = 0.5735 (TML), respectively. LBA17 LBA17 There is a strong correlation between TMB determined by TSO500 and TML panels with F1CDx, particularly for tumours with low PD-L1 expression. The range of TMB values is lower with TSO500 and TML, for samples determined TMBhigh by F1CDx. Cut-off values may be lowered for these panels in order to meet F1CDx TMB categories. Fundacion para la Investigacion Biomedica del Hospital Doce de Octubre, Madrid, Spain. Bristol-Myers Squibb. E.M. Garrido-Martin: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Speaker Bureau / Expert testimony: Illumina. S. Hernandez Prieto: Honoraria (institution): Roche; Honoraria (institution): Thermo Fisher; Honoraria (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (institution): Bristol-Myers Squibb; Honoraria (institution): AbbVie. S. Ponce Aix: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: AstraZeneca. P. Garrido: Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boerhinger Ingelheim; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy: AbbVie; Advisory / Consultancy, Research grant / Funding (institution): Guardant Health; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (institution), Advisory / Consultancy: Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Sysmex; Honoraria (institution), Advisory / Consultancy: Blueprint Medicines; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Speaker Bureau / Expert testimony: Gilead; Speaker Bureau / Expert testimony: Rovi; Honoraria (institution): Pharmamar; Honoraria (institution): Celgene; Honoraria (institution): Sanofi; Honoraria (institution): GSK, Theradex Oncology. F. Lopez-Rios: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Thermo Fisher; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy: Bayer. L. Paz-Ares: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Pharmamar; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Celgene; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Servier; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Sysmex; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Sanofi; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Ipsen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Adacap; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Bayer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Blueprint. All other authors have declared no conflicts of interest.

5 September 2021 in European Respiratory Journal
Verified
Conference Paper
Closed access
JPJavier Ramos Paradas
Javier Ramos Paradas
DGDavid Gomez-Sanchez
David Gomez-Sanchez
ARAranzazu Rosado
Aranzazu Rosado
IFIrene Ferrer
Irene Ferrer
NCNuria Carrizo
Nuria Carrizo
EGEva M Garrido-Martin
Eva M Garrido-Martin
Non-Small-Cell Lung Cancer (NSCLC) leads cancer incidence and mortality. Immune checkpoint blockers showed promising results, yet responders cannot be accurately selected as robust predictive biomarkers are lacking. Our hypothesis is that molecular aberrations of tumor cells impact the immune microenvironment. This association may be crucial to predict response to immunotherapy. We evaluated a retrospective cohort of clinically annotated early stage NSCLC (N=196). We described its immune profile by immunohistochemistry and an immune markers RNAseq panel, and its molecular profile by Next Generation Sequencing (DNA/RNAseq). We defined novel groups of patients with distinct molecular features and two main immunophenotypes. Immune hot tumors had higher infiltration of CD4+, CD8+ and CD20+ cells, while cold tumors accrued mutations in ARID1A, CARD11, CCND1, FGF3, FGF10, FGF19, MYC, NF1, NOTCH1, PIK3CA, PIK3CB and TFRC, dependent on histology. These features, together with the differential expression of immune markers, defined potential predictive biomarkers. Hot tumors were identified by genes related to adaptive immune response (CD28, FCRLA, JCHAIN, LY9, MS4A1, SLAMF7, TNFRSF9, TNFRSF17), antigen presentation (CD1C, CD1D), immune chemotaxis (CCL20, CCR4, CCR6) and immune regulation (CD53, PDCD1, SH2D1A). Cold tumors were defined by genes involved in angiogenesis (VEGFA), cell cycle (BUB1, CCNB2, FOXM1, MAD2L1, TOP2A), growth/survival (IGF1R), DNA replication/repair (KIAA0101) and iron metabolism (HMBS, TFRC). We defined novel patient groups in NSCLC based on multiparametric features and identified potential predictive biomarkers of response to immunotherapy.

13 August 2020 in Cancer Research
Verified
Conference Paper
Closed access
JPJavier Ramos Paradas
Javier Ramos Paradas
DGDavid Gomez-Sanchez
David Gomez-Sanchez
ARAranzazu Rosado
Aranzazu Rosado
IFIrene Ferrer
Irene Ferrer
NCNuria Carrizo
Nuria Carrizo
EGEva M. Garrido-Martin
Eva M. Garrido-Martin
Lung cancer leads cancer mortality, being Non-Small-Cell Lung Cancer (NSCLC) the most prevalent subtype. Immunotherapy with checkpoint inhibitors has shown promising results in NSCLC, yet this benefit is restricted to a subset of patients. Robust predictive biomarkers of response are lacking. We seek a multiparametric biomarker signature. We hypothesize that specific molecular alterations of NSCLC tumor cells have a deep impact on the immune microenvironment. Describing this relationship is critical to predict response to immunotherapy. We evaluated 178 samples from a retrospective cohort of clinically annotated early stage NSCLC patients. We analyzed their immune profile by immunohistochemistry and a RNAseq immune panel. In parallel, we defined their molecular aberrations and Tumor Mutational Burden by Next Generation Sequencing. We integrated our multiparametric data with Multi-Omics Factor Analysis. Adenocarcinomas (N=80) cluster in 4 groups with two main immunophenotypes. Key factors of this clustering are TOP2A, MKI67, CCNB2, CDK1, JCHAIN, VEGFA, PCLAF, KRT7, FOXM1, BUB1. The proimmune tumors upregulate genes related to immune activation (CD40LG, CD28, MS4A1), signaling (CD79B), chemoattraction (CXCR2), antigen presentation (CD1C, HLA-DQA2), inflammatory cytokines (IL2, IL1B), and immune cells (CD19). Oppositely, the protumoral samples overexpress genes involved in cell cycle (CCNB2, FOXM1, CDKN2A, CDKN3), immune inhibition (CD276), angiogenesis (VEGFA) and proliferation (AKT1, EGFR, PIK3CA, MTOR, MKI67). Regarding molecular characterization, KRAS mutation is enriched in the proimmune subset, while the protumoral one gathers mutations in ARID1A and ALK. Squamous cell carcinomas (N=98) cluster in 4 groups with two main immunophenotypes. Critical factors of this clustering are TRIM29, FOXM1, KRT5, TOP2A, MKI67, TFRC, CCNB2, CD44, EGFR, KREMEN1. The proimmune tumors upregulate genes involved in immune signaling (CD3D, CD3E, CD3G, CD79A, CD79B), activation (CD40LG, CD27, MS4A1), chemoattraction (CXCR5, CXCL13), antigen presentation (CD1C, HLA-DMA/DPB1/DRA/DMB/DOB), inflammatory cytokines (IFNG, IL17F, IL21), immune cells (CD8A, CD19) and immunomodulation (ICOS). Contrarily, the protumoral samples upregulate genes related to cell cycle (FOXM1, BUB1, CCNB2, CDK1), immune cells (FOXP3), angiogenesis (VEGFA), apoptosis (BCL2), immunomodulation (PD-L1) and proliferation (AKT1, MTOR, MYC, PIK3CA, MKI67). Of note, the proimmune subset has higher infiltration of CD8+, CD4+ and B cells. The protumoral one accrues mutations in TFRC, PIK3CA, PIK3CB, FGF3, FGF10. In conclusion, we performed a comprehensive description of novel NSCLC subgroups based on multiparametric data that will improve prediction of response to immunotherapy. Citation Format: Javier Ramos-Paradas, David Gomez-Sanchez, Aranzazu Rosado, Irene Ferrer, Nuria Carrizo, Ana B. Enguita, Maria T. Muñoz, Urbicio Perez-Gonzalez, Ivan Martinez, Luis Paz-Ares, Eva M. Garrido-Martin. Comprehensive multiparametric analysis of non-small cell lung cancer describes novel genotype-immunophenotype relationships and provides putative biomarker signatures of response to checkpoint blockade [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2006.